Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BMcV who wrote (3054)	5/27/1999 9:36:00 AM
From: Biomaven	Read Replies (2) of 10280

I agree with several thread participants that the IgE story has nothing to do with SEPR's weakness. If this was perceived as a serious threat to the antihistamine market, we would have seen major weakness in SGP compared with the other pharmas. This has clearly not been the case: techstocks.com For an example of the superficial "analysis" that has helped drive the stock down, let me offer this, quoted from a glowing article in TheStreet by Herb Greenberg (who usually knows better) about one Jordan Kimmel, president of Magnet Investing in TheStreet: Then there was the time, shortly after he called on McKesson, that he sent out a warning about Sepracor (SEPR:Nasdaq), the now-fallen biotech giant, which lost its air after Johnson & Johnson (JNJ:NYSE) chose not to exercise its option to co-promote a new version of Sepracor's allergy drug. "It had high debt, extremely decreased revenues, insiders didn't own a share and somehow this stock was going up because of momentum players. As soon as the momentum broke, I went short." Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next